Condition: Non Small Cell Lung Cancer · NSCLC · KRAS G12C · Sponsor: Ryan Gentzler, MD
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
This description comes directly from the study's public registry record.
Ryan Gentzler, MD, MS · 434-924-4251 · rg2uc@uvahealth.org
Amber Ryba · 317-634-5842 · aryba@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| University of Virginia Health System | Charlottesville, Virginia, United States | Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06248606